Observation On The Short-term Efficacy Of Recombinant Human Endostatin Combined With Chemotherapy In The Treatment Of Advanced Squamous Cell Lung Cancer

Objective:To observe the short-term efficacy of recombinant human endostatin(endostar)combined with chemotherapy in the treatment of advanced lung squamous cell carcinoma,and whether endostar can increase the toxicity related to chemotherapy and affect the level of serum tumor markers.Methods: From September 2016 to October 2018,patients with squamous cell carcinoma diagnosed pathologically and clinically staged as stage IIIB or IV were enrolled in the Department of respiratory medicine,Yijishan Hospital Affiliated to Wan Nan Medical College.They were randomly divided into two groups: 31 cases in the experimental group were treated with Endostar combined with DP regimen,34 cases in control group received DP regimen chemotherapy.According to RECIST 1.1,the disease control rate of two groups of patients after 2 cycles of chemotherapy was evaluated.The WHO toxicity assessment criteria were used to determine the levels of chemotherapy-related toxicity and serum squamous cell associated antigen(SCC)and cytokeratin 19 fragment(CYFRA21-1).Results:Endostar combined with chemotherapy group(31 cases in the experimental group)and single chemotherapy group(34 cases in the control group).Both the experimental group and the control group completed two cycles of chemotherapy.There were 3 cases(9.7%),15 cases(48.4%)with stable disease,13 cases(41.9%) with partial remission,and 0 cases with complete remission.The disease control rate(DCR)was 90.3%,the objective remission rate(ORR)was 41.9%,and 17 cases(54.8%)with chemotherapy-related side effects.In the control group,there were 10 cases(29.4%),15 cases(44.1%)with stable disease,9 cases(26.5%)with complete remission.DCR was 70.6%,ORR was 26.5%,and chemotherapy-related side effects were 19 cases(55.9%).Compared with DCR in the control group,DCR in the experimental group was significantly lower than that in the control group(P < 0.05).There was no significant difference in ORR between the two groups.There was no significant difference in serum SCC and CYFRA21-1 levels between the two groups before chemotherapy(P > 0.05),but there was significant difference in serum SCC and CYFRA21-1 levels between the experimental group and the control group after treatment(P < 0.05).There was no significant difference between the two groups in the occurrence of chemotherapy-related side effects.There was no significant difference between smoking and disease progression.Conclusion:Endorstar combined with chemotherapy can increase the DCR of patients with advanced lung squamous cell carcinoma,and reduce the levels of SCC and CYFRA21-1 in serum.Endorstar combined with chemotherapy does not increase the toxicity and side effects associated with chemotherapy in patients with advanced lung squamous cell carcinoma.Smoking is not related to the progression of disease in patients with advanced lung squamous cell carcinoma...